The FDA was not convinced in 2011 by Teva's ADAGIO trial. Results were very odd and difficult to explain. E.g., whereas 1 mg showed some neuroprotection 2 mg show none at all.

It is hard to account for this kind of finding. Why would there not be a dose-response effect?

There are a variety of new, potentially effective neuroprotective agents being tested. I wouldn't bet the farm on Azilect.

Howard